INTENDED FOR UK HEALTHCARE PROFESSIONALS
OUR PRODUCTS >
Asthma: Licensed in adults and
adolescents 12 years and above
COPD: Licensed in adults
18 years and above
OVERVIEW – ATIMOS® pMDI
Atimos® is available in a pressurised metered-dose inhaler (pMDI), delivering 100 inhalations of 12 micrograms of formoterol fumarate dihydrate per device.
Indications for Atimos®1
For the long-term symptomatic treatment of persistent, moderate to severe asthma in patients requiring regular bronchodilator therapy in combination with long-term anti-inflammatory therapy (inhaled and/or oral glucocorticoids).
Glucocorticoid therapy should be continued on a regular basis.
Atimos® is indicated for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD).
- Atimos Summary of Product Characteristics. Chiesi Limited.